Evidence map›Paper›PMID 33968762›Full record

ReviewFrontiers in oncology2021

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.

Michela Roberto, Andrea Botticelli, Martina Panebianco, Anna Maria Aschelter, Alain Gelibter, Chiara Ciccarese, Mauro Minelli, Marianna Nuti, Daniele Santini, Andrea Laghi and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Michela RobertoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Andrea BotticelliDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Martina PanebiancoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Anna Maria AschelterMedical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy.
Alain GelibterMedical Oncology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Chiara CiccareseDepartment of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Mauro MinelliDepartment of Medical Oncology, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.
Marianna NutiDepartment of Experimental Medicine, University of Rome Sapienza Rome, Rome, Italy.
Daniele SantiniDepartment of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
Andrea LaghiDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Silverio TomaoDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Paolo MarchettiDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITAgostino Gemelli University Polyclinic · ITAzienda Ospedaliera San Giovanni Addolorata · ITAzienda Ospedaliera Sant'Andrea · ITUniversità Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic sc"enario of metastatic renal cell cancer (mRCC) has noticeably increased, ranging from the most studied molecular target therapies to those most recently introduced, up to immune checkpoint inhibitors (ICIs). The most recent clinical trials with an ICI-based combination of molecular targeted agents and ICI show how, by restoring an efficient immune response against cancer cells and by establishing an immunological memory, it is possible to obtain not only a better radiological response but also a longer progression-free and overall survival. However, the role of tyrosine kinase inhibitors (TKIs) remains of fundamental importance, especially in patients who, for clinical characteristics, tumor burden and comorbidity, could have greater benefit from the use of TKIs in monotherapy rather than in combination with other therapies. However, to use these novel options in the best possible way, knowledge is required not only of the data from the large clinical trials but also of the biological mechanisms, molecular pathways, immunological mechanisms, and methodological issues related to both new response criteria and endpoints. In this complex scenario, we review the latest results of the latest clinical trials and provide guidance for overcoming the barriers to decision-making to offer a practical approach to the management of mRCC in daily clinical practice. Moreover, based on recent literature, we discuss the most innovative combination strategies that would allow us to achieve the best clinical therapeutic results.

Indexed as

immune checkpoints inhibitornew biomarkersrenal cancer carcinomatargeted therapytyrosine kinase inhibitor (TKI)

Identifiers

PMID33968762
PMCPMC8100507
OpenAlexW3154038964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.